PATENT CLAIM ANALYSIS

Application Number: 16012372
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-04
Patent Classification: ["514", "183000"]

Abstract:
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Claim (Index 5):
The method of  claim 1 , wherein liposomal irinotecan has a maximum plasma concentration of 37 micrograms/mL.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.22857
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15241128', '14406776', '14851111', '14844500', '14812950']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8503502200106636
- 35 USC 102 Novelty (BERT): 0.7225847714962687
- Combined Prediction Score: 0.8375736751592241
- Mean Citation Score: 628.0000880000001
- Max Citation Score: 844.3667
- Similarity Product: 763.3028029928803

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test